NO173974C - Fremgangsmaate ved fremstilling av en cytotoksisk blanding - Google Patents

Fremgangsmaate ved fremstilling av en cytotoksisk blanding

Info

Publication number
NO173974C
NO173974C NO874569A NO874569A NO173974C NO 173974 C NO173974 C NO 173974C NO 874569 A NO874569 A NO 874569A NO 874569 A NO874569 A NO 874569A NO 173974 C NO173974 C NO 173974C
Authority
NO
Norway
Prior art keywords
cytotoxic agent
preparing
instilled
cytotoxic composition
cytotoxic
Prior art date
Application number
NO874569A
Other languages
English (en)
Norwegian (no)
Other versions
NO173974B (no
NO874569D0 (no
NO874569L (no
Inventor
Dominic Man-Kit Lam
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of NO874569D0 publication Critical patent/NO874569D0/no
Publication of NO874569L publication Critical patent/NO874569L/no
Publication of NO173974B publication Critical patent/NO173974B/no
Publication of NO173974C publication Critical patent/NO173974C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NO874569A 1986-11-04 1987-11-03 Fremgangsmaate ved fremstilling av en cytotoksisk blanding NO173974C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92731886A 1986-11-04 1986-11-04

Publications (4)

Publication Number Publication Date
NO874569D0 NO874569D0 (no) 1987-11-03
NO874569L NO874569L (no) 1988-05-05
NO173974B NO173974B (no) 1993-11-22
NO173974C true NO173974C (no) 1994-03-02

Family

ID=25454561

Family Applications (1)

Application Number Title Priority Date Filing Date
NO874569A NO173974C (no) 1986-11-04 1987-11-03 Fremgangsmaate ved fremstilling av en cytotoksisk blanding

Country Status (12)

Country Link
EP (1) EP0267005B1 (da)
JP (1) JPH07121878B2 (da)
AT (1) ATE83666T1 (da)
AU (1) AU608257B2 (da)
CA (1) CA1338777C (da)
DE (1) DE3783211T2 (da)
DK (1) DK575487A (da)
ES (1) ES2053561T3 (da)
FI (1) FI95203C (da)
GR (1) GR3007052T3 (da)
IE (1) IE60436B1 (da)
NO (1) NO173974C (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
WO1995003783A1 (en) * 1990-03-06 1995-02-09 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044167A3 (en) * 1980-07-14 1982-04-21 The Regents Of The University Of California Antibody targeted cytotoxic agent
US4432751A (en) * 1982-03-05 1984-02-21 Baylor College Of Medicine Monoclonal antibodies against lens epithelial cells and preventing proliferation of remnant lens epithelial cells after extracapsular extraction
ATE60233T1 (de) * 1983-09-15 1991-02-15 Univ Leland Stanford Junior Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung.
EP0173648A3 (en) * 1984-08-30 1988-04-27 Ciba-Geigy Ag New monoclonal antibodies to glycoconjugates, processes for their production, and applications
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins

Also Published As

Publication number Publication date
IE60436B1 (en) 1994-07-13
DK575487A (da) 1988-05-05
NO173974B (no) 1993-11-22
EP0267005B1 (en) 1992-12-23
EP0267005A2 (en) 1988-05-11
FI95203C (fi) 1996-01-10
AU608257B2 (en) 1991-03-28
EP0267005A3 (en) 1989-11-08
IE872977L (en) 1988-05-04
JPS63211239A (ja) 1988-09-02
ES2053561T3 (es) 1994-08-01
FI95203B (fi) 1995-09-29
GR3007052T3 (da) 1993-07-30
ATE83666T1 (de) 1993-01-15
FI874852A0 (fi) 1987-11-03
DE3783211D1 (de) 1993-02-04
NO874569D0 (no) 1987-11-03
FI874852L (fi) 1988-05-05
NO874569L (no) 1988-05-05
AU8066687A (en) 1988-05-05
JPH07121878B2 (ja) 1995-12-25
CA1338777C (en) 1996-12-10
DE3783211T2 (de) 1993-04-29
DK575487D0 (da) 1987-11-03

Similar Documents

Publication Publication Date Title
ES479206A1 (es) Un procedimiento para la preparacion de n-heterociclil-4- piperidinamina.
FI823720L (fi) Hydroxisubstituerad 2-bensotiazolsulfonamid foer lokalbehandling av oekat tryck i oegat
IE44773L (en) Theophylline compositions
IE35642B1 (en) A process for the preparation of new alpha-aminopenicillins and such penicillins and intermediates and pharmaceutical preparations
IE830467L (en) Monoclonal antibodies against lens epithelial cells
NO173974C (no) Fremgangsmaate ved fremstilling av en cytotoksisk blanding
ES8600272A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-sulfamoilbenzo (b) tiofeno.
GB1013442A (en) Organic dyestuffs containing ethionylamino groups and process for their manufacture
SE434739B (sv) Forfarande enligt patentet 7602406-6 (publ nr 426059) for framstellning av ren druvsyra och meso-vinsyra
GB810232A (en) Improvements in artificial intraocular lenses
ES450799A1 (es) Un procedimiento para la preparacion de nuevas 3-fenilespino(esobenzofuran-1,4'-piperidemo) sulfenamidas y derivados.
AU7039981A (en) Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye
DE2965292D1 (en) Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
OH et al. Complications associated with intravitreal silicone oil injection
Vrabec et al. Ring-shaped alkali burns of the rabbit cornea: Epithelial and endothelial changes
EP0372071A4 (en) Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction.
GB574279A (en) Process for the manufacture of derivatives of thiophane-3-one-4-carboxylic acid esters
ADLER et al. PATHOLOGIC STUDY OF OCULAR LESIONS DUE TO LEWISITE (β-CHLOROVINYLDICHLOROARSINE): Changes With and Without BAL (2, 3-Dimercaptopropanol) Therapy
JPS55102516A (en) Remedy for glaucoma
GB1121479A (en) Process for the dry cleaning of fibrous material and a composition therefor
JPS52263A (en) Process for preparation of 1-alkanesulfonyloxy alkyl-2-alkyl-3-dipheny lmethylenepyrrolidine and its salts
ES8503645A1 (es) Procedimiento de preparacion de carbamatos vinilicos
ES485302A1 (es) Procedimiento para la preparacion de halogenosulfamoilbence-nos
LIM et al. Pars Plana Vitrectomy in Pars Planitis and Posterior Uveitis
KIM et al. Clinical Results of Mode-locked Nd: YAG Laser Posterior Capsulotomy

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees